1. Home
  2. MHO vs CRNX Comparison

MHO vs CRNX Comparison

Compare MHO & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MHO

M/I Homes Inc.

HOLD

Current Price

$126.48

Market Cap

3.3B

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$40.94

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHO
CRNX
Founded
1976
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.9B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
MHO
CRNX
Price
$126.48
$40.94
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$160.00
$76.63
AVG Volume (30 Days)
178.6K
1.0M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
14.74
N/A
Revenue
$4,417,781,000.00
$1,039,000.00
Revenue This Year
$0.66
$720.10
Revenue Next Year
$6.97
$184.67
P/E Ratio
$8.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$102.44
$25.83
52 Week High
$158.92
$57.99

Technical Indicators

Market Signals
Indicator
MHO
CRNX
Relative Strength Index (RSI) 51.72 59.94
Support Level $125.38 $39.35
Resistance Level $127.81 $45.32
Average True Range (ATR) 3.66 1.47
MACD 0.75 0.61
Stochastic Oscillator 86.73 95.81

Price Performance

Historical Comparison
MHO
CRNX

About MHO M/I Homes Inc.

M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: